Renal effects of immune checkpoint inhibitors

被引：74

作者：

Izzedine, Hassan ^{[1
]}

Mateus, Christine ^{[2
]}

Boutros, Celine ^{[2
]}

Robert, Caroline ^{[2
]}

Rouvier, Philippe ^{[3
]}

Amoura, Zahir ^{[4
]}

Mathian, Alexis

机构：

[1] Monceau Pk Int Clin Paris, Dept Nephrol, Paris, France

[2] Gustave Roussy Inst, Dept Oncol, Villejuif, France

[3] Hop La Pitie Salpetriere, Dept Pathol, Paris, France

[4] Hop La Pitie Salpetriere, Dept Internal Med 2, Paris, France

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2017年 / 32卷 / 06期

关键词：

checkpoint blockade; immunotherapy; ipilimumab; nivolumab; pembrolizumab; OVERCOMING IMMUNOLOGICAL-TOLERANCE; ACUTE INTERSTITIAL NEPHRITIS; MELANOMA TARGETING CTLA-4; ANTI-PD-1; ANTIBODY; PHASE-II; IPILIMUMAB; NIVOLUMAB; SAFETY; BLOCKADE; PEMBROLIZUMAB;

D O I：

10.1093/ndt/gfw382

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

Recent advances in immune checkpoint inhibitor (ICPI) development have led to major improvements in oncology patient outcomes. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are two essential immune checkpoint receptors. Ipilimumab and tremelimumab (anti-CTLA-4-blocking antibodies) and pembrolizumab and nivolumab (antibodies targeting PD-1 receptors) have already been approved by US Food and Drug Administration in several malignancies. Two different forms of ICPI-induced renal damage have been identified, including acute (granulomatous) tubulointerstitial nephritis and immune complex glomerulonephritis. The observed acute renal damage can be reversed upon ICPI drug discontinuation and renal function can recover back to normal following the introduction of systemic corticosteroid treatment. Any delay in treating this complication could result in definitive and irreversible renal injury.

引用

页码：936 / 942

页数：7

共 72 条

[1] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[2]

Bavi P, 2016, MODERN PATHOL, V29, p4A

[3] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[4] The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].

Bennett, CL ;

Christie, J ;

Ramsdell, F ;

Brunkow, ME ;

Ferguson, PJ ;

Whitesell, L ;

Kelly, TE ;

Saulsbury, FT ;

Chance, PF ;

Ochs, HD .

NATURE GENETICS, 2001, 27 (01) :20-21

[5] IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena [J].

Bennett, CL ;

Ochs, HD .

CURRENT OPINION IN PEDIATRICS, 2001, 13 (06) :533-538

[6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[7] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[8] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[9] Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse [J].

Brunkow, ME ;

Jeffery, EW ;

Hjerrild, KA ;

Paeper, B ;

Clark, LB ;

Yasayko, SA ;

Wilkinson, JE ;

Galas, D ;

Ziegler, SF ;

Ramsdell, F .

NATURE GENETICS, 2001, 27 (01) :68-73

[10] Endocrine Side Effects Induced by Immune Checkpoint Inhibitors [J].

Corsello, Salvatore Maria ;

Barnabei, Agnese ;

Marchetti, Paolo ;

De Vecchis, Liana ;

Salvatori, Roberto ;

Torino, Francesco .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) :1361-1375

← 1 2 3 4 5 6 7 8 →